Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (2331)	9/5/2002 10:31:26 PM
From: Miljenko Zuanic	Read Replies (2) \| Respond to of 2515

I was correct on C225 and IMCL from 97 to 02. You are forming opinion on C225 from IMCL trading scandal, management screw-up and BMS wrong calculations. Also, you are making conclusion about drug based on ~200 purely designed and executed PII CC trial. If you have something of substance on drug, say clearly. But you are repeating yourself like broken record. So, expert, what is prediction on Iressa? No survival and ~15% response rate!